Migraine-Drug Deal Hype Turns Into a Giant Headache

Bookmark
(Bloomberg Opinion) -- Biohaven Pharmaceutical Holding Co. has rapidly transformed from one of biotech’s darlings into a cautionary tale of overheated M&A hype. 
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.